U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H20FN5O2.C4H6O4
Molecular Weight 475.4701
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TRELAGLIPTIN SUCCINATE

SMILES

OC(=O)CCC(O)=O.CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=CC(F)=CC=C3C#N)C1=O

InChI

InChIKey=OGCNTTUPLQTBJI-XFULWGLBSA-N
InChI=1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H20FN5O2
Molecular Weight 357.3821
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24622716 | https://www.ncbi.nlm.nih.gov/pubmed/21186796 | https://www.takeda.com/news/2015/20150528_6997.html

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor used for the treatment of type 2 diabetes mellitus. Trelagliptin (as the salt Trelagliptin succinate) was approved for use in Japan in March 2015. Takeda, the company that developed Trelagliptin, chose to not get approval for the drug in the USA and EU.

Originator

Curator's Comment: # Takeda Pharmaceutical Company

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27487
Gene ID: 1803.0
Gene Symbol: DPP4
Target Organism: Homo sapiens (Human)
4.0 nM [IC50]
4.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Zafatek

Approved Use

Unknown

Launch Date

2015
PubMed

PubMed

TitleDatePubMed
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
2016
Patents

Sample Use Guides

Usually, for adults, 100 mg of trelagliptin is orally administered once a week
Route of Administration: Oral
Trelagliptin (1 M) were incubated 0, 5, 15, 30 minute at 37 °C in phosphate buffer (50 mM, pH 7.4) containing rat or human liver microsomes (1 mg/mL protein) and NADPH (4 mM). Metabolic stability of Trelagliptin was assayed by LC/MS
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:30:42 GMT 2023
Edited
by admin
on Sat Dec 16 01:30:42 GMT 2023
Record UNII
4118932Z90
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRELAGLIPTIN SUCCINATE
USAN   WHO-DD  
USAN  
Official Name English
SYR-111472 SUCCINATE
Code English
BUTANEDIOIC ACID, COMPD. WITH 2-((6-((3R)-3-AMINO-1-PIPERIDINYL)-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-PYRIMIDINYL)METHYL)-4-FLUOROBENZONITRILE (1:1)
Common Name English
SYR111472 SUCCINATE
Code English
SYR-472
Code English
TRELAGLIPTIN SUCCINATE [USAN]
Common Name English
TRELAGLIPTIN SUCCINATE [JAN]
Common Name English
Trelagliptin succinate [WHO-DD]
Common Name English
ZAFATEK
Brand Name English
TRELAGLIPTIN SUCCINATE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98086
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C152724
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
JAPANESE REVIEW
ZAFATEK
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY APPROVE MARCH 2015
FDA UNII
4118932Z90
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
USAN
YY-29
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
EVMPD
SUB179791
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
MERCK INDEX
m11930
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
CAS
1029877-94-8
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
SMS_ID
100000165897
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID00145602
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL1650443
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
PUBCHEM
44183569
Created by admin on Sat Dec 16 01:30:42 GMT 2023 , Edited by admin on Sat Dec 16 01:30:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY